Center for Inquiry Testifies at FDA Hearing on Regulation of Homeopathy
April 20, 2015
The Center for Inquiry (CFI) was invited and today delivered oral testimony at the Food and Drug Administration's first review of its policies regarding the regulation of homeopathic products in more than 25 years.
Michael De Dora, director of CFI's Office of Public Policy, delivered CFI's testimony during on the first of a two-day public hearing at the FDA's White Oak Campus in Silver Spring, MD. His testimony, however, was presented not only behalf of CFI, "but also on behalf of dozens of doctors and scientists associated with CFI and its affiliate program, the Committee for Skeptical Inquiry, with whom we work on these matters."
In his testimony, De Dora briefly reviewed the scientific evidence on homeopathy, illustrated the harm caused by homeopathy, and proposed actions the FDA should take to hold homeopathic products to the same standards as non-homeopathic drugs in order to fulfill its mandate to protect the American public. He concluded:
"... homeopathy is unsupported by scientific evidence, ineffective in treating illness and, when relied upon instead of actual medicine, dangerous and even deadly. To ensure the protection of the American public, the FDA should rely on its well-established regulatory system to require homeopathic products to meet the same standards as non-homeopathic drugs, or at the least mandate labeling for homeopathic products which states: the product’s claimed active ingredients in plain English; and that the product has not been evaluated by the FDA for safety or effectiveness. The American public deserves as much from the agency tasked with protecting them."
You can read CFI's full testimony here.
To learn more about CFI's advocacy of science-based medicine over pseudoscience, visit our Keep Healthcare Safe and Secular campaign website.